Moreover, CYP8B1 downregulation, but not CYP7A1,32 decrease in the serum levels of unconjugated BAs and secondary BAs,33 and hepatic BA increase,34 have been reported in patients with MASH. This evidence concerns the gene CYP8B1 and metabolic dysfunction-associated steatohepatitis.